0000905148-24-001654.txt : 20240529 0000905148-24-001654.hdr.sgml : 20240529 20240529192045 ACCESSION NUMBER: 0000905148-24-001654 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240525 FILED AS OF DATE: 20240529 DATE AS OF CHANGE: 20240529 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LAPOINTE ANTHONY GREGG CENTRAL INDEX KEY: 0001331860 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-29889 FILM NUMBER: 241000307 MAIL ADDRESS: STREET 1: PO BOX 83216 CITY: GAITHERSBURG STATE: MD ZIP: 20883-3216 FORMER NAME: FORMER CONFORMED NAME: Lapointe Gregg Anthony DATE OF NAME CHANGE: 20050630 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RIGEL PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001034842 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943248524 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BOULEVARD, SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-624-1100 MAIL ADDRESS: STREET 1: 611 GATEWAY BOULEVARD, SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 form4.xml X0508 4 2024-05-25 0001034842 RIGEL PHARMACEUTICALS INC RIGL 0001331860 LAPOINTE ANTHONY GREGG C/O RIGEL PHARMACEUTICALS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 true false Common Stock 2024-05-25 4 A 0 25000 0 A 100000 D Stock Option (Right to Buy) 0.9075 2024-05-25 4 A 0 30000 0 A 2034-05-25 Common Stock 30000 30000 D The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. /s/ Raymond Furey (Attorney-in-Fact) 2024-05-29